Latest Insider Transactions at Eye Point Pharmaceuticals, Inc. (EYPT)
This section provides a real-time view of insider transactions for Eye Point Pharmaceuticals, Inc. (EYPT). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of EyePoint Pharmaceuticals, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of EyePoint Pharmaceuticals, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 23
2023
|
Anthony P Adamis |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+50.0%
|
-
|
|
May 30
2023
|
Ye Liu |
SELL
Open market or private sale
|
Indirect |
1
|
$6
$6.0 P/Share
|
|
Feb 09
2023
|
Goran Ando |
BUY
Exercise of conversion of derivative security
|
Direct |
3,250
+28.51%
|
-
|
|
Feb 09
2023
|
John B. Landis |
BUY
Exercise of conversion of derivative security
|
Direct |
3,000
+20.83%
|
-
|
|
Feb 09
2023
|
Wendy F Dicicco |
BUY
Exercise of conversion of derivative security
|
Direct |
3,000
+28.85%
|
-
|
|
Feb 09
2023
|
Dario A. Paggiarino Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,744
-6.57%
|
$14,976
$4.17 P/Share
|
|
Feb 09
2023
|
Dario A. Paggiarino Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,800
+16.95%
|
-
|
|
Feb 09
2023
|
David R Guyer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,000
+28.85%
|
-
|
|
Feb 09
2023
|
David Scott Jones SVP & Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,956
-5.41%
|
$11,824
$4.17 P/Share
|
|
Feb 09
2023
|
David Scott Jones SVP & Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,967
+16.41%
|
-
|
|
Feb 09
2023
|
Jay S. Duker President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,148
-6.42%
|
$16,592
$4.17 P/Share
|
|
Feb 09
2023
|
Jay S. Duker President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
11,967
+16.36%
|
-
|
|
Feb 09
2023
|
Nancy Lurker |
BUY
Exercise of conversion of derivative security
|
Direct |
37,533
+9.41%
|
-
|
|
Feb 09
2023
|
George Elston Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,800
+21.0%
|
-
|
|
Nov 01
2022
|
Jay S. Duker President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,479
-17.31%
|
$22,395
$5.42 P/Share
|
|
Nov 01
2022
|
Jay S. Duker President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
15,258
+37.09%
|
-
|
|
Mar 14
2022
|
Michael Craig Pine Chief Corp Dev.&Strat. Officer |
BUY
Open market or private purchase
|
Direct |
1,000
+50.0%
|
$12,000
$12.21 P/Share
|
|
Feb 28
2022
|
Nancy Lurker |
BUY
Exercise of conversion of derivative security
|
Direct |
12,466
+7.66%
|
-
|
|
Feb 28
2022
|
Dario A. Paggiarino Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,294
-6.49%
|
$11,646
$9.95 P/Share
|
|
Feb 28
2022
|
Dario A. Paggiarino Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,105
+17.07%
|
-
|
|
Feb 28
2022
|
David Scott Jones SVP & Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,130
-6.75%
|
$10,170
$9.95 P/Share
|
|
Feb 28
2022
|
David Scott Jones SVP & Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,105
+19.7%
|
-
|
|
Feb 21
2022
|
Nancy Lurker |
BUY
Exercise of conversion of derivative security
|
Direct |
13,717
+9.05%
|
-
|
|
Feb 09
2022
|
Nancy Lurker |
BUY
Exercise of conversion of derivative security
|
Direct |
17,533
+12.38%
|
-
|
|
Feb 09
2022
|
David Scott Jones SVP & Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,473
-10.45%
|
$14,730
$10.13 P/Share
|
|
Feb 09
2022
|
David Scott Jones SVP & Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,966
+26.05%
|
-
|
|
Feb 09
2022
|
Dario A. Paggiarino Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,721
-9.8%
|
$17,210
$10.13 P/Share
|
|
Feb 09
2022
|
Dario A. Paggiarino Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,966
+22.04%
|
-
|
|
Feb 09
2022
|
Jay S. Duker President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
4,966
+31.86%
|
-
|
|
Feb 09
2022
|
George Elston Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,721
-15.2%
|
$17,210
$10.13 P/Share
|
|
Feb 09
2022
|
George Elston Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,966
+30.49%
|
-
|
|
Feb 09
2022
|
Goran Ando |
BUY
Exercise of conversion of derivative security
|
Direct |
2,750
+35.95%
|
-
|
|
Feb 09
2022
|
Wendy F Dicicco |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+36.23%
|
-
|
|
Feb 09
2022
|
David R Guyer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+36.23%
|
-
|
|
Feb 09
2022
|
John B. Landis |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+22.94%
|
-
|
|
Nov 15
2021
|
Nancy Lurker |
SELL
Open market or private sale
|
Direct |
10,000
-8.81%
|
$200,000
$20.15 P/Share
|
|
Jun 22
2021
|
Douglas Evan Godshall |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+23.77%
|
-
|
|
Jun 14
2021
|
Dario A. Paggiarino Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
417
-3.2%
|
$3,753
$9.72 P/Share
|
|
Jun 14
2021
|
Dario A. Paggiarino Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,420
+9.84%
|
-
|
|
Jun 14
2021
|
Nancy Lurker |
BUY
Exercise of conversion of derivative security
|
Direct |
4,500
+3.81%
|
-
|
|
Feb 28
2021
|
Nancy Lurker |
BUY
Exercise of conversion of derivative security
|
Direct |
12,467
+10.26%
|
-
|
|
Feb 28
2021
|
John B. Landis |
BUY
Exercise of conversion of derivative security
|
Direct |
1,900
+24.36%
|
-
|
|
Feb 28
2021
|
David R Guyer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,900
+50.0%
|
-
|
|
Feb 28
2021
|
Douglas Evan Godshall |
BUY
Exercise of conversion of derivative security
|
Direct |
1,900
+25.62%
|
-
|
|
Feb 28
2021
|
Wendy F Dicicco |
BUY
Exercise of conversion of derivative security
|
Direct |
1,900
+50.0%
|
-
|
|
Feb 28
2021
|
Goran Ando |
BUY
Exercise of conversion of derivative security
|
Direct |
2,150
+50.0%
|
-
|
|
Feb 28
2021
|
David Scott Jones SVP & Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,702
-18.74%
|
$17,020
$10.81 P/Share
|
|
Feb 28
2021
|
David Scott Jones SVP & Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,105
+31.13%
|
-
|
|
Feb 28
2021
|
Dario A. Paggiarino Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,423
-10.93%
|
$14,230
$10.81 P/Share
|
|
Feb 28
2021
|
Dario A. Paggiarino Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,105
+23.98%
|
-
|